Topic: Nycomed International Management GmbH
TOKYO/LONDON (Reuters) - Japan's largest drugmaker Takeda Pharmaceutical is buying privately held Nycomed for 9.6 billion euros ($13.7 billion), boosting its presence in emerging markets and adding a newly approved lung-disease drug.The agreed deal is the biggest overseas purchase by a Japanese ...
Japan's Takeda Pharmaceutical said Thursday it reached a 9.6 billion euro ($13.6 billion) deal to buy Swiss drugmaker Nycomed in what would be one of the biggest overseas acquisitions by a Japanese firm.Takeda said it will finance part of the transaction through ...
Japan's top drugmaker Takeda Pharmaceutical has reached a $12 billion deal to buy Swiss drugmaker Nycomed, a report said Thursday.Takeda has struck a basic agreement and is expected to make a formal announcement soon, the Nikkei business daily said in its evening ...
TOKYO (Reuters) - Japan's largest drugmaker Takeda Pharmaceutical Co is in talks to buy privately-held Swiss rival Nycomed in a deal that could be valued at about $14.2 billion, Bloomberg said, citing two people with knowledge of the matter.Negotiations are at an ...
Pantoprazole (Sold as Pantotab ; Pantopan ; Protium ; Protonix ; Pantozol ; Pantor ; Pantoloc ; Astropan ; Controloc ; Pantecta ; Inipomp ; Somac ; Ulcepraz ; Pantodac ) is a proton pump inhibitor drug used for short-term treatment of ...
The BioBay Investor Forum selected two early stage life science companies based in China as the " Swiss biopharma Nycomed bought a majority 51.3% of Guangdong Techpool Bio-Pharma, saying the acquisition will increase its activity in China (see story). In return for ...
Shares of Forest Laboratories Inc. fell Thursday after federal health experts voted against recommending approval for the company's experimental lung disease treatment.. Previously, a panel voted 9-6 that Daxas appeared effective for treating the disease.. Jefferies & Co. analyst Corey Davis reaffirmed ...
FRX), an international pharmaceutical manufacturer and marketer, today announced that diluted earnings per share equaled $0.61 in the second quarter of fiscal 2010. Reported earnings per share includes a charge for a new product license fee of $100.0 million, or $0.33 per ...
FRX), an international manufacturer and marketer of pharmaceutical products and Nycomed, a privately owned pharmaceutical company, will host a conference call at 7:15 AM EDT on Friday, August 28, 2009. Dr. Lawrence Olanoff, President and Chief Operating Officer of Forest Labs, Dr. ...
Nycomed agreed with Sanofi-Aventis and Zentiva to purchase 20 branded generic products in several Central and Eastern European countries. The agreement will notably strengthen Nycomed's market position in particular in the Czech Republic and Slovakia. In an asset transfer transaction, Nycomed will ...
